Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 7

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 7
---
2,194,971) 
    $(67,361,778) 
    $(2,531,868)

    Convertible
    Preferred Stock  

    Additional  
       
    Total 

    Series
    Seed  
    Series
    A  
    Common
    Stock  
    Paid-in  
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Deficit  
    Deficit 
  
    Balance
    at December 31, 2023 (Predecessor) 
     5,155,703  
    $4,077,560  
     22,764,764  
    $38,023,784  
     292  
    $-  
    $1,032,126  
    $(43,089,821) 
    $(42,057,695)
  
    Stock
based compensation 
     -  
     -  
     -  
     -  
     -  
     -  
     4,431  
     -  
     4,431 
  
    Net
    loss 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     (572,211) 
     (572,211)
  
    Balance
    at February 13, 2024 (Predecessor) 
     5,155,703  
    $4,077,560  
     22,764,764  
    $38,023,784  
     292  
    $-  
    $1,036,557  
    $(43,662,032) 
    $(42,625,475)

See
accompanying notes to the condensed consolidated financial statements

Reflects
a 1-for-100 reverse stock split effective January 8, 2025 and 1-for-20 reverse stock split effective June 13, 2025

4

CERO
THERAPEUTICS HOLDINGS, INC.

CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOW

(Unaudited)

    For the 
    Six Months 
    ended 
    June 30